Safety Study of Single Administration Intravenous Treatment for Influenza

• Status: Terminated
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-7100, a candidate treatment for influenza.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sarepta Therapeutics; Sarepta Therapeutics, Inc.
• Treatments: Radavirsen

Criteria

Inclusion Criteria:

• Male or female and between the ages of 18 and 50 years in good general health

• Volunteers must be willing to use barrier methods of contraception or be of non-childbearing potential

• Volunteers must be willing to undergo a urine screen for drugs of abuse

Exclusion Criteria:

• Pregnancy or breastfeeding.

• Any clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis

• Positive test for human immunodeficiency virus, hepatitis B or hepatitis C or known history of HIV infection